Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
niraparib + tebotelimab
- Development stage
- Discontinued
- Lead developer
- MacroGenics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Niraparib + tebotelimab is an investigational combination therapy consisting of niraparib, an oral poly(ADP-ribose) polymerase (PARP) inhibitor, and tebotelimab (MGD013), a first-in-class bispecific monoclonal antibody targeting PD-1 and LAG-3. Developed by Zai Lab in collaboration with MacroGenics, this combination aims to leverage the synergistic effects of PARP inhibition and dual immune checkpoint blockade. Niraparib induces DNA damage and promotes an inflammatory tumor microenvironment, while tebotelimab reactivates exhausted T cells by simultaneously blocking the PD-1 and LAG-3 pathways. The combination was evaluated in Phase 1b trials for advanced solid tumors, including gastric cancer, triple-negative breast cancer, biliary tract carcinoma, and endometrial carcinoma. However, due to limited antitumor activity, further clinical development for this specific combination has been discontinued.
- Brand names
- Zejula
- Other names
- niraparib + tebotelimabtebotelimab + niraparib
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on niraparib + tebotelimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on niraparib + tebotelimab.